Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

The Role of Genetics in Advancing Cardiometabolic Drug Development

Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment

Pharmacogenomics revolutionizing cardiovascular therapeutics: A narrative review

Pharmacogenetics to guide cardiovascular drug therapy

State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response

Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention

Using human genetics to improve safety assessment of therapeutics

Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9

Progress of Pharmacogenomics and Individual Drug Design

From target discovery to clinical drug development with human genetics

The Challenge and Importance of Integrating Drug–Nutrient–Genome Interactions in Personalized Cardiovascular Healthcare

Promise and Peril of a Genotype-First Approach to Mendelian Cardiovascular Disease

Prioritising genetic findings for drug target identification and validation

Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?

Proceedings of the 2017 International Conference of Precision Health and Precision Nutrition

PHARMACOGENOMICS: Driving Personalized Medicine

Insights into pharmacogenetics, drug-gene interactions, and drug-drug-gene interactions

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medications

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval

New Therapeutic Approaches in the Management of Cardiometabolic Diseases: Bringing the Concepts Together.

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.